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Amitifadine (EB-1010, formerly DOV 21,947) is a serotonin-preferring triple reuptake inhibitor with
a relative potency to inhibit serotonin, norepinephrine, and dopamine uptake of w1:2:8, respectively.
This 6-week, multicenter, randomized, double-blind, parallel, placebo-controlled study evaluated the
efﬁcacy and tolerability of amitifadine in 63 patients with major depressive disorder. Eligible patients
(17-item Hamilton Depression Rating Scale [HAMD-17]  22 at baseline) were randomized to amitifadine
25 mg twice daily (BID) for 2 weeks, then 50 mg BID for 4 weeks or placebo. Mean baseline scores in the
modiﬁed intent-to-treat population (n ¼ 56) were 31.4 for the Montgomery-Åsberg Depression Rating
Scale (MADRS), 29.6 for the HAMD-17, and 25.4 for the Derogatis Interview for Sexual Functioning e Self
Report (DISF-SR). At the end of the 6-week double-blind treatment, estimated least squares mean change
from baseline (mixed-model repeated measures [MMRM]) in MADRS total score was statistically
signiﬁcantly superior for amitifadine compared to placebo (18.2 vs. 22.0; p ¼ 0.028), with an overall
statistical effect size of 0.601 (Cohen’s d). Amitifadine also was statistically signiﬁcantly superior to
placebo (p ¼ 0.03) for the Clinical Global Impression of Change e Improvement. An anhedonia factor
score grouping of MADRS Items 1 (apparent sadness), 2 (reported sadness), 6 (concentration difﬁculties),
7 (lassitude), and 8 (inability to feel) demonstrated a statistically signiﬁcant difference in favor of ami-
tifadine compared to placebo (p ¼ 0.049). No differences were observed between treatments in DISF-SR
scores. Amitifadine was well-tolerated. Two patients on each treatment discontinued the study early due
to adverse events; however, no serious adverse events were reported. This initial clinical trial in patients
with severe major depression demonstrated signiﬁcant antidepressant activity with amitifadine,
including attenuating symptoms of anhedonia, and a tolerability proﬁle that was comparable to placebo.
The efﬁcacy and tolerability of amitifadine for major depressive disorder are being investigated in
additional clinical trials.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The introduction ofﬂuoxetine in the late 1980smarked thedebut
of a new class of antidepressants, the selective serotonin reuptake
inhibitors (SSRIs) (Wong et al., 1995). SSRIs increase the synaptic
availability of serotonin by inhibiting the serotonin transporter
(5-HTT). The serotonin transporter is one member of a family of 12: þ1 617 507 5617.
-NC-ND license.trans-membrane spanning neurotransmitter transporters
(Kuzelova et al., 2010). Uptake by the 5-HTT is the principalmeans of
removing serotonin from the synapse, thereby terminating its
action as a neurotransmitter (Kuzelova et al., 2010). As a class, SSRIs
are generally better tolerated, safer, and easier to use than the ﬁrst
generation agents, such as tricyclic antidepressants (TCAs) and
monoamine oxidase inhibitors (MAOIs). In double-blind placebo-
controlled studies, however, only about 50% of patients respond to
a given SSRI (Walsh et al., 2002), and approximately one-third of
patients achieve clinical remission (Thase, 2003). Moreover, the
typical onset of action is slow. For those patients who respond, 2e4
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effect. SSRI administration is associated with troublesome weight
gain with some agents and sexual dysfunction (Fava, 2000; Rosen
et al., 1999). These side effects can contribute to a signiﬁcant
degree of non-compliance to treatment regimens. Moreover, about
30% of patients treated successfully with SSRIs continue to report
signiﬁcant cognitive impairment, such as an inability to stay focused
and difﬁculty with recall, word-ﬁnding, and mental acuity (Fava
et al., 2006).
The role of norepinephrine in mood disorders has been recog-
nized for almost 50 years (Schildkraut and Kety, 1967). Preclinical
studies indicate a pivotal role for the prefrontal cortex, which
requires noradrenergic stimulation to function optimally, in
modulating high level learning, memory, attention, and emotions
(Blier, 2001; El Mansari et al., 2010; Gamo and Arnsten, 2011). Many
TCAs inhibit the reuptake of both NE and 5-HT with varying
potencies, but possess off-target actions that limit safety and
tolerability (Anderson, 2000). Dual uptake inhibitors such as ven-
lafaxine, milnacipran, and duloxetine lack the safety liabilities of
TCAs, but are only marginally superior to SSRIs for antidepressant
efﬁcacy (Cipriani et al., 2009; Nemeroff et al., 2008).
Dopamine plays a central role in reward, motivation, mood
regulatory functions, working memory, attention, and executive
functions (Schultz, 2007). Converging lines of evidence indicate that
enhancing dopaminergic neurotransmission can diminish anhe-
donia (a core symptom of major depression) as well as improve
cognition and motivation (Skolnick, 2005; Skolnick and Basile,
2007; Dunlop and Nemeroff, 2007), and symptoms of anhedonia
respondpoorly to SSRIs (SheltonandTomarken, 2001;McCabe et al.,
2010). Bupropion, a dopamine and norepinephrine reuptake
inhibitor, and dopamine agonists such as pramipexole have
demonstrated antidepressant activities (Tremblay and Blier, 2006).
A growing body of literature suggests that antidepressants with
more than one mechanism of action are more effective than a drug
with a single mechanism (Blier et al., 2010; Rush et al., 2006;
Papakostas et al., 2007). Major depression is a heterogeneous and
complex disorder attributed to genetic, developmental, and envi-
ronmental factors (Millan, 2009; Perovic et al., 2010). In addition to
treating the core symptoms of depression, a need exists to treat
other symptoms including insomnia, fatigue, anxiety, memory and
cognitive impairment while avoiding side effects. Because of the
diversity of symptoms and co-morbid symptoms, the majority of
depressed patients are unlikely to respond to drugs acting at a single
receptor (Millan, 2009; Perovic et al., 2010). Dopamine, as well as
serotonin and norepinephrine, is involved in the pathophysiology
and treatment of depression (Skolnick, 2005), which has given rise
to a new class of antidepressants that simultaneously inhibit sero-
tonin, norepinephrine, and dopamine (Skolnick et al., 2003a; Guiard
et al., 2009; Millan, 2009; Marks et al., 2008;). It has been proposed
that activity from all three monoamines may account for an
enhanced antidepressant response. The concept of broad spectrum
antidepressants, whereby all three monoaminergic systems (sero-
tonin, norepinephrine, and dopamine) are engaged to act in concert
to improve symptoms of depression, has been partially validated in
the Sequenced Treatment Alternatives to Relieve Depression
(STAR*D) study sponsored by the National Institutes of Mental
Health (Trivedi et al., 2006; Rush et al., 2006). Patients who did not
achieve sufﬁcient symptomatic relief with the SSRI, citalopram,
were able to achieve the highest level of remission with bupropion
augmentation compared to the other augmentations including
buspirone and cognitive therapy. These encouraging results
conﬁrmed the conceptual foundation for the development of broad
spectrum antidepressants (Skolnick et al., 2003a).
Amitifadine ((1R,5S)-(þ)-1-(3,4-dichlorophenyl)-3-azabicyclo
[3.1.0]hexane hydrochloride, formerly called DOV 21947) isa “broad spectrum” antidepressant or serotonin-preferring triple
reuptake inhibitor (Skolnick et al., 2003b). Amitifadine inhibits the
function of the transport proteins responsible for clearing dopa-
mine, serotonin, and norepinephrine from the synaptic cleft.
Microdialysis studies show that amitifadine inhibits reuptake of all
three neurotransmitters (Bymaster and McKinney, 2010), and
inhibition of ex vivo binding of amitifadine that is consistent with
in vitro binding has been demonstrated (Lengyel et al., 2008).
However, no currently marketed antidepressants inhibit the uptake
of all three transmitters at pharmacologically relevant doses.
Furthermore, amitifadine exhibits a relative potency to inhibit
serotonin, norepinephrine, and dopamine reuptake of w1:2:8,
respectively. The concentration required to inhibit uptake (IC50) in
recombinant human transporters was reported as: 12 nM for
serotonin, 23 nM for norepinephrine, and 96 nM for dopamine
(Skolnick et al., 2003b). It was hypothesized that amitifadine may
express unique antidepressant activities in humans, with enhanced
efﬁcacy such as improvement of anhedonia. Anhedonia is
presumably linked to a deﬁcit in mesocorticolimbic dopaminergic
function, and dopaminergic activity is related to a reduced liability
to induce sexual dysfunction, weight gain, sleepiness, fatigue, and
cognitive dysfunction, adverse effects typically associated with
SSRIs (Skolnick, 2005). The present study reports the results of the
ﬁrst proof-of-concept clinical trial of amitifadine in patients with
major depressive disorder.
2. Methods
The studywas conducted at 11 sites in Romania, 2 sites in Serbia,
and 7 sites in the United States. The study was conducted in
accordancewith the Declaration of Helsinki (Edinburgh, 2000, with
paragraph 29 as clariﬁed in Washington, DC, 2002, and note of
clariﬁcation added on paragraph 30 in Tokyo, 2004). The protocol
was approved by an appropriate ethical committee for each site,
and written informed consent of all participants was obtained after
the nature of the procedures had been fully explained and prior to
study participation.
2.1. Study design
This was a multicenter, randomized, double-blind, placebo-
controlled, parallel-group study of amitifadine in patients with
major depressive disorder (MDD). After satisfactory completion of
screening, patients underwent a 7-day, single-blind, placebo run-in
period to determine study medication compliance and placebo
response. All patients took placebo capsules twice daily (BID)
during the run-in period. Following completion of baseline
assessments, patients were randomized in a 1:1 ratio to amitifadine
or placebo, using an interactive voice response system. Study
medications were provided as capsules of amitifadine 25 mg and
placebo that appeared identical. Patients were instructed to take 2
capsules in the morning and 2 capsules in the evening, each day
during the study. For the ﬁrst 2 weeks of the 6-week double-blind
treatment period, patients randomized to amitifadine took 25 mg
BID (as 1 amitifadine capsule and 1 placebo capsule), and for the
remaining 4 weeks they took 50 mg BID (2 amitifadine capsules).
During the treatment period, study visits occurred at days 8, 15, 22,
29, and 43. All patients again took placebo capsules BID for a 7-day
single-blind placebo follow-up period, with the ﬁnal study visit at
day 50.
2.2. Patient selection
Adult outpatients or inpatients between ages 18 and 65 years
(inclusive) were eligible if they were diagnosed with major
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of Mental Disorders, 4th Edition, Revised (American Psychiatric
Association, 2000) and MINI International Neuropsychiatric Inter-
view for major depressive disorder (Sheehan et al., 1998). Patients
were required to have a history of recurrent depressive episode of
at least 2 months in duration. They also were required to have
a previous signiﬁcant clinical improvement to at least one antide-
pressant treatment. In addition, they had a 17-item Hamilton
Depression Rating Scale (HAMD-17; Hamilton, 1960) total
score  22 with severity score of 2 on Item 1 at screening, single-
blind placebo run-in, and baseline; HAMD-17 score reduction15%
between placebo run-in and baseline; Hamilton Anxiety Rating
Scale (HAM-A; Hamilton, 1959) total score <17 at screening; body
mass index 35 kg/m2 and body weight >45 kg at screening; and
study medication compliance of 80%e120% during the single-blind,
placebo run-in period. In addition, any patient receiving psycho-
therapy must have been on the same treatment for at least 3
months prior to screening and the therapy must have remained
unchanged throughout the study. Women of childbearing potential
were required to use adequate contraception and to have a negative
serum pregnancy test at screening.
Excluded were patients judged to be a suicide risk, including
those with a score of 4 on the HAMD-17 suicide item. Also excluded
were patients with >15% reduction in the HAMD-17 score between
screening and the baseline visit, those known to be resistant to
antidepressant treatment (failed 2 previous antidepressant treat-
ments from different classes given for at least 4 weeks) or elec-
troconvulsive therapy, or who had electroconvulsive therapy
within 1 year before screening. Patients with psychotic depression
or those who had taken ﬂuoxetine within 4 weeks prior to
screening or other antidepressants within 2 weeks or 5 half-lives of
the antidepressant (whichever was longer) before baseline were
excluded. Patients with any other psychiatric disorder including
substance use disorders were excluded. Study participants were
required to be free of major clinically signiﬁcant medical and/or
other psychiatric illnesses. Patients with a history of signiﬁcant
drug or food allergy or hypersensitivity were excluded.Table 1
Disposition of patients.
Number (%) of patients
Amitifadine Placebo Total
Randomized 34 29 63
Completed 16 (47.1) 17 (58.6) 33 (52.4)
Reason for discontinuation
Adverse event 3 (8.8) 3 (10.3) 6 (9.5)
Lost to follow-up 1 (2.9) 1 (3.4) 2 (3.2)
Patient request 3 (8.8) 3 (10.3) 6 (9.5)
Protocol deviation 0 1 (3.4) 1 (1.6)
Investigator request 5 (14.7) 5 (17.3) 10 (15.9)
Therapeutic failure 2 (5.9) 0 2 (3.2)2.3. Outcome measures
The primary efﬁcacy outcome was the change in the total score
on the Montgomery Asberg Depression Rating Scale (MADRS;
Montgomery and Åsberg, 1979) from baseline to the end of treat-
ment. Rater training on the MADRS was provided to all raters in
this study, and only raters who completed the training and quali-
ﬁcation program were allowed to conduct MADRS assessments.
Other efﬁcacy outcomes included HAMD-17 total score and indi-
vidual subscales; the Clinician’s Global Impression of Change e
Improvement score (CGI-I) and Severity score (CGI-S; Guy, 1976);
and an anhedonia factor, based on MADRS items 1 (apparent
sadness), 2 (reported sadness), 6 (concentration difﬁculties), 7
(lassitude), and 8 (inability to feel). Response was deﬁned as 50%
reduction (improvement) from baseline on the MADRS or HAMD-
17 total score, or a CGI-I score 2. Remission was deﬁned as
MADRS  12, HAMD-17  7, or CGI-S  2. HAMD-17 assessments
were conducted via an Interactive Voice Response System (IVRS) at
the study site.
Safety and tolerability assessments included treatment-
emergent adverse events based on the classiﬁcation of the
Medical Dictionary for Regulatory Activities (MedDRA), discontin-
uations due to adverse events, vital signs, laboratory evaluations,
and electrocardiograms (ECGs). The Derogatis Interview for Sexual
Functioning e Self Report (DISF-SR) was administered at baseline
and at weeks 2, 4, and 6 (Derogatis and Melisaratos, 1979).2.4. Statistical analysis
The modiﬁed intent-to-treat (MITT) population was deﬁned as
all randomized patients with any conﬁrmed dosing and MADRS
data from at least one post-baseline visit. The safety population
comprised all randomized patients who received study drug.
Comparisons between treatment groups based on MADRS (the
primary efﬁcacy parameter), HAMD-17, anhedonia, DISF-SR, CGI-I,
and CGI-S scores were analyzed using a mixed-model repeated
measures (MMRM) analysis model including factors for patient,
visit, treatment arm, and baseline value as a covariate (Mallinckrodt
et al., 2003, 2007; Siddiqui et al., 2009). Results from this model are
presented as adjusted least-squares means. Comparisons between
groups were made at each post-baseline visit using model-based
contrasts and adjusted degrees of freedom. For these analyses, no
explicit data imputations weremade prior to the analysis. Response
and remission categorical data were analyzed using chi-square
tests. Inferential analyses of safety data were conducted with
analysis of covariance (ANOVA) models or chi-square tests.
Two-tailed alphawas set to 0.05. All analyses were conducted using
SAS version 9.2.
The planned sample size of 200 patients (100 per group) was
determined based on ﬁndings of previous multicenter, placebo-
controlled studies of patients with MDD with a similar study
design. The power computation indicated that 100 patients per
treatment group would yield a power of more than 80% to detect
a difference with a 0.38 point overall difference in improvement
(effect size) in the MITT population (Cohen’s d) between placebo
and amitifadine, which was consistent with meta-analytic esti-
mates of the effect size from studies of antidepressants (Bech et al.,
2000; Turner et al., 2008).3. Results
The study was initiated in April 2008 and was halted by the
sponsor, DOV Pharmaceuticals, early in December 2008 due to lack
of funding. At the time of study termination, 63 patients had been
randomized, and 61 had received study drug (Table 1). The Safety
population (n ¼ 61) included 33 amitifadine-treated patients and
28 placebo-treated patients. TheMITT population (n¼ 56) included
30 amitifadine-treated patients and 26 placebo-treated patients.
Five patients were excluded from the MITT population because
they discontinued the study before having any post-baseline
MADRS assessment.
The demographic and baseline characteristics were similar
between the groups for the safety populations (Table 2). The
majority of patients were female and Caucasian, with an average
age of approximately 49 years. At baseline, patients were consid-
ered severely depressed as evidenced by a meanMADRS score 30
and a mean HAMD-17 score  25.
Table 2
Demographic and baseline characteristics (Safety population).
Characteristic Amitifadine
(n ¼ 33)
Placebo
(n ¼ 28)
Mean (SD) age, years 48.2 (9.4) 49.5 (6.9)
Gender, n (%)
Male 8 (24.2) 9 (32.1)
Female 25 (75.8) 19 (67.9)
Ethnic origin, n (%)
Caucasian 31 (93.9) 28 (100)
Black 1 (3.0) 0 (0.0)
Hispanic 1 (3.0) 0 (0.0)
MADRS score, mean (SD)a 30.6 (4.5) 32.2 (4.2)
HAMD-17 score, mean (SD)a 28.8 (3.8) 30.4 (4.5)
CGI-S score, mean (SD)a 4.5 (0.5) 4.8 (0.8)
Anhedonia factor score, mean (SD)a,b 12.7 (2.1) 13.7 (1.6)
SD ¼ Standard deviation.
a MITT population (n ¼ 56).
b Anhedonia factor score ¼ MADRS items 1, 2, 6, 7 and 8.
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For the primary outcome measure, treatment with amitifadine
was associated with a signiﬁcantly (p ¼ 0.028) greater improve-
ment in the MADRS total score at week 6 compared with placebo
(Table 3 and Fig. 1). The effect size was 0.63 (Cohen’s d).
Signiﬁcantly greater improvement also was observed with
amitifadine compared to placebo for both the CGI-I score
(p ¼ 0.030) and the anhedonia factor score (p ¼ 0.049) at week 6
(Table 3 and Fig. 2). A consistent trend for superiority of amitifadine
was observed for the HAMD-17 and CGI-S, but the differences
between treatments were not signiﬁcant.
A signiﬁcantly (p ¼ 0.038) greater remission rate for the CGI-S
was observed with amitifadine compared with placebo at week 6
(Table 4). Despite that lack of statistical signiﬁcance, the proportion
of patients experiencing response or remission was 2- to 3-fold
greater with amitifadine than with placebo at week 6 on the
MADRS. At the 1-week post-treatment assessment, the MADRS
response rate was signiﬁcantly (p ¼ 0.030) greater and the CGI-S
remission rate was signiﬁcantly (p ¼ 0.020) greater with amitifa-
dine than with placebo.3.2. Safety and tolerability
Two (6.1%) patients on amitifadine and two (7.1%) on placebo
discontinued treatment due to adverse events. The two patients
treated with amitifadine discontinued early due to rash. One
patient treated with placebo discontinued early due to rash and
another discontinued early due to nausea and palpitations. No
serious adverse events or deaths were reported. A total of 43
adverse events were reported in 10 (30.3%) patients with amitifa-
dine and 37 adverse events were reported in 11 (39.3%) patients
with placebo. The most common treatment-emergent adverseTable 3
Least square adjusted means with differences in primary and secondary efﬁcacy measur
Measure Least squares adjusted mean (Standard error)
Amitifadine
(n ¼ 30)
Placebo
(n ¼ 26)
Differe
(95% C
MADRS 18.2 (1.21) 22.0 (1.24) 3.8 (0.
HAMD-17 14.9 (1.40) 18.0 (1.46) 3.1 (
Anhedonia factor 7.9 (0.50) 9.3 (0.50) 1.4 (0.
CGI-I 2.1 (0.20) 2.8 (0.20) 0.6 (0.
CGI-S 3.3 (0.15) 3.5 (0.15) 0.2 (
CI ¼ conﬁdence interval; NA ¼ not available
Statistical analysis using mixed-measure repeated model (MMRM) analysis.event was headache occurring in 9.1% of patients with amitifadine
and 10.7% with placebo. Various other adverse events occurred
with an incidence of 6.1% with amitifadine and at twice the rate of
placebo including diarrhea, nausea, rash, and abdominal pain
(Table 5). Amitifadine was associated with small mean changes
from baseline in vital signs and laboratory analytes that were not
clinically signiﬁcant (Table 6). A statistically signiﬁcant difference
(p ¼ 0.017) in change from baseline in standing diastolic blood
pressure was observed between amitifadine (3 mmHg) vs.
placebo (2.8 mmHg) that was not considered clinically relevant.
Mean heart rate increased by 1.55 bpm with amitifadine and
decreased by 1.68 bpm with placebo. Mean body weight increased
a non-signiﬁcant 0.078 kg with amitifadine and 0.04 kg with
placebo.
DISF-SR scores were stratiﬁed by low mean baseline scores
(<25, indicating signiﬁcant rate of sexual dysfunction) versus high
mean baseline scores (25, indicating satisfying rate of sexual
function). In both the low baseline and high baseline groups, no
signiﬁcant differences were observed between amitifadine and
placebo (Fig. 3).
4. Discussion
The present study is a proof-of-concept trial that assessed the
treatment outcomes of amitifadine, one of a class of “serotonin-
preferring” triple reuptake inhibitor” to enter clinical development
in patients with major depressive disorder. Despite early termina-
tion because of a lack of funding, the results of this placebo-
controlled study demonstrated that treatment with amitifadine
initiated at 50 mg daily dose and titrated to 100 mg daily dose is
efﬁcacious in the treatment of patients with severe major depres-
sive disorder. Amitifadine was superior to placebo for the primary
endpoint and several secondary endpoints as measured by stan-
dard validated instruments. In this trial, the difference between
amitifadine and placebo for mean change from baseline in MADRS
score was 3.8, which was higher than mean changes of 3.0e3.25
reported in meta-analyses of randomized clinical trials with SSRIs
(Kennedy et al., 2006; Taylor et al., 2006). Another approach to
comparing results between studies is the effect size. An extensive
review and meta-analysis of data from antidepressant clinical trials
submitted to the FDA reported an overall effect size of 0.32 for
active drug vs. placebo, which varied from 0.37 for published
studies to 0.15 for unpublished studies (Turner et al., 2008). The
treatment difference on the primary endpoint, MADRS total score,
demonstrated amuchmore robust effect size of0.601 (Cohen’s d),
which is about double that of the average0.32 effect size achieved
with standard antidepressant drugs (Turner and Rosenthal, 2008;
Bech et al., 2000). An analysis of depression by baseline severity
reported an effect size of 0.47 among patients with very severe
depression (HAMD-17  23) compared with effect sizes of 0.11 and
0.17 for less severe depression (Fournier et al., 2010). Both the effect
size and NNT estimates support a strong antidepressant signal withes at week 6 (MITT population).
nce
I)
P-value Effect
Size
Number needed
to treat
41, 7.26) 0.028 0.601 5.42
0.87, 7.12) 0.125 0.421 6.82
01, 2.82) 0.049 0.542 NA
06, 1.18) 0.030 0.593 NA
0.21, 0.66) 0.306 0.280 NA
Table 4
Response and remission rates LOCF (MITT population).
Outcome Week 6 1-week post-treatment
Amitifadine
(n ¼ 30)
Placebo
(n ¼ 26)
P-valuea Amitifadine
(n ¼ 30)
Placebo
(n ¼ 26)
P-valuea
Responseb
MADRS 9 (30.0) 3 (11.5) 0.093 11 (36.7) 3 (11.5) 0.030
HAMD-17 14 (46.7) 8 (32.0) 0.269 15 (50.0) 8 (32.0) 0.178
CGI-I 16 (53.3) 14 (53.9) 0.969 17 (56.7) 14 (53.9) 0.832
Remissionc
MADRS 6 (20.0) 2 (7.7) 0.189 8 (26.7) 2 (7.7) 0.065
HAMD-17 5 (16.7) 4 (16.0) 0.947 7 (23.3) 3 (12.0) 0.278
CGI-S 7 (23.3) 1 (3.9) 0.038 8 (26.7) 1 (3.9) 0.020
LOCF ¼ last observation carried forward.
a Chi-square test.
b Response was deﬁned as 50% reduction (improvement) from baseline on the
total score on the MADRS or HAMD-17, or CGI-I score  2.
c Remission was deﬁned as MADRS  12, HAMD-17  7, or CGI-S  2.
Fig. 1. Weekly MADRS total scores, mixed-model repeated measures, least squares
means (MITT population, n ¼ 56).
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the therapeutic dose range. Therefore, further dosing levels, espe-
cially lower doses, should be studied.
In addition to the overall treatment effect, several secondary
exploratory hypotheses were evaluated including effects on anhe-
donia based on aMADRS anhedonia factor score. The design feature
of this early clinical study with amitifadine incorporated a forced
dose titration during the ﬁrst two weeks of therapy, which made it
difﬁcult to evaluate the effect of a 50 mg daily dose of amitifadine.
More importantly, this design prevented a proper evaluation of
onset of action of the 100 mg daily dose due to confounding from
the low initial dose during the ﬁrst two weeks of treatment.
However, the evaluation of onset of action will become more
important in future studies, especially as the optimal therapeutic
dosing regimen with amitifadine is elucidated.
Patients with major depressive disorder often suffer from loss of
interest in pleasurable activities, commonly described as anhe-
donia, which has been identiﬁed as a core symptom of depression
(Dichter, 2010). Researchers have identiﬁed a group of symptoms,
termed the anhedonia factor, which are extracted from the MADRS
and have been shown to be sensitive to change with treatment
(Hammond, 1998; Parker et al., 2003). A factor analysis in several
cohorts of depressed patients from clinical trials has established the
validity of the anhedonia factor in patients with major depression
(Hammond, 1998; Parker et al., 2003; Gabryelewicz et al., 2004).Fig. 2. Weekly anhedonia factor scores, mixed-model repeated measures, least squares
means (MITT population, n ¼ 56).The analysis of the anhedonia factor score shows that amitifadine is
efﬁcacious in improving a core domain of affective deﬁcit that is
presumed to be related to a hypodopaminergia (Dichter, 2010;
Perovic et al., 2010; Millan, 2009). These results support the
hypothesis that broad spectrum antidepressants are useful in
treating a wider range of symptom domains in depression than
mono- or dual-acting antidepressants, in particular the question-
able efﬁcacy of SSRIs in patients with anhedonia (Shelton and
Tomarken, 2001; Nutt et al., 2007; McCabe et al., 2010). Other
triple reuptake inhibitors have failed to demonstrate antidepres-
sant efﬁcacy in clinical trials. It can be hypothesized that the
positive results obtained with amitifadine in this trial are a function
of the unbalanced effects on reuptake inhibition with amitifadine,
which is in contrast to the balanced effect on all 3 neurotransmit-
ters with earlier failed drugs such as GSK372475.
Despite the modest sample size of this proof-of-concept study,
the adverse event proﬁle of amitifadine was similar to that of
placebo, suggesting that amitifadine 100 mg daily was well-
tolerated. As predicted (Skolnick, 2005), treatment with amitifa-
dine was not associated with changes in sexual function. Of most
interest, patients who had preserved sexual functions at baseline
did not experience worsening in their sexual function. This is an
important feature of amitifadine since sexual dysfunction has been
reported with many existing antidepressants and sexual dysfunc-
tion is a cause of non-compliance and early treatment failure
(Clayton et al., 2002; Montejo et al., 2001; Williams et al., 2006;
Serretti and Chiesa, 2011). It is well described that increased
dopamine levels in the medial preoptic area are necessary for
sexual motivation and facilitate sexual behavior, while dopamine
antagonists are associated with erectile dysfunction (Rotenberg,
2010; Serretti and Chiesa, 2009). The mechanism is uncertain, butTable 5
Treatment-emergent adverse events occurring in 5% of EB-1010-treated patients
or at least twice the rate of placebo (Safety population).
Number (%) of patients
Amitifadine
(n ¼ 33)
Placebo
(n ¼ 28)
Headache 3 (9.1) 3 (10.7)
Abdominal pain 2 (6.1) 1 (3.6)
Anxiety 2 (6.1) 1 (3.6)
Diarrhea 2 (6.1) 1 (3.6)
Irritability 2 (6.1) 1 (3.6)
Nausea 2 (6.1) 1 (3.6)
Rash 2 (6.1) 1 (3.6)
Upper respiratory tract infection 2 (6.1) 1 (3.6)
Emotional disturbance 2 (6.1) 0 (0.0)
Table 6
Changes from baseline in selected vital signs and laboratory values atWeek 6 (Safety
population).
Assessment, Units Mean (SD) change P-valuea
Amitifadine
(n ¼ 33)
Placebo
(n ¼ 28)
Supine systolic blood pressure,
mm Hg
2.58 (9.19) 2.28 (9.39) 0.904
Supine diastolic blood pressure,
mm Hg
0.38 (7.10) 0.48 (7.90) 0.961
Standing systolic blood pressure,
mm Hg
0.069 (9.75) 2.12 (12.86) 0.509
Standing diastolic blood pressure,
mm Hg
3.00 (8.03) 2.80 (9.23) 0.017
Supine pulse, beats per minute 1.55 (7.94) 1.68 (8.08) 0.145
Weight, kg 0.078 (2.80) 0.04 (2.5) 0.965
Total cholesterol fasting, mg/dL 5.86 (24.67) 11.36 (23.66) 0.412
LDL cholesterol fasting, mg/dL 4.29 (22.43) 9.96 (23.65) 0.374
Triglycerides fasting, mg/dL 12.00 (39.61) 7.80 (55.41) 0.750
SD ¼ standard deviation.
a P values were calculated using analysis of variance with treatment group as
main effect.
P. Tran et al. / Journal of Psychiatric Research 46 (2012) 64e71 69appears to be related to increased activation of 5-HT2 receptors in
response to increased 5-HT signaling (Clayton and Montejo, 2006;
Serretti and Chiesa, 2009). Another notable ﬁnding is that although
this was a short-term study and was not designed speciﬁcally to
assess the effects of amitifadine on weight, amitifadine was not
associated with any weight changes. A trial of longer duration with
more subjects will be required to more fully address the issue of
weight changes with amitifadine. Weight changes, especially
weight gain, are unwanted side effects of many antidepressants and
may contribute to co-morbidities and non-adherence to treatment
regimens (Fava, 2000; Serretti and Mandelli, 2010). Dopamine
activity is known to suppress feeding activity and produce ano-
rexant effects in animal models (Axel et al., 2010).
Amitifadine 100 mg daily dose was associated with a small
increase in mean heart rate but no change in blood pressure was
observed. The mean heart rate increase of 1.5 beats/minute
suggests that the 100mg daily dose is within the physiologic range,
and this pharmacodynamic effect is probably related to the known
pharmacologic effect of amitifadine on norepinephrine reuptake,
which in turn activates noradrenergic receptors in the heart (Thase
et al., 2005; Roose and Miyazaki, 2005).
This proof-of-concept trial with amitifadine in patients with
severe major depression demonstrated signiﬁcant antidepressantFig. 3. DISF-SR scores stratiﬁed by visit and baseline sexual function, last observation
carried forward (MITT population; n ¼ 56).activity and attenuated symptoms of anhedonia. This robust efﬁ-
cacy with amitifadine was combined with a tolerability proﬁle that
was similar to that of placebo. Thus, the efﬁcacy and tolerability of
amitifadine warrant additional clinical trials among patients with
major depressive disorder to further elucidate its therapeutic
proﬁle.
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